NRXP · NRX Pharmaceuticals, Inc. · Insider Trading

Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. 33.3% of the Options shall vest on June 1, 2026, 33.3% shall vest on December 1, 2026, and the remaining 33.3% shall vest on December 1, 2027.

Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest on April 9, 2026, subject to continued service to the Issuer.

Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest on April 9, 2026, subject to continued service to the Issuer.

Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. 1/3 of the Options shall vest on the first anniversary of the grant date, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to continued

Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest on April 9, 2026, subject to continued service to the Issuer.

Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest in three equal annual installments beginning on February 7, 2026.

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.

Consists of (i) 8,336 shares of Common Stock held by Samuel David Gorovitz 2017 Irrevocable Trust, (ii) 8,336 shares of Common Stock held by Jeremy Paul Gorovitz 2017 Irrevocable Trust, (iii) 8,336 shares of Common Stock held by Marisa Shey Gorovitz 2017 Irrevocable Trust, (iv) 51,678 shares of Common Stock held by Elizabeth Gorovitz. Aaron Gorovitz is the trustee of the Samuel David Gorovitz 2017 Irrevocable Trust, the Jeremy Paul Gorovitz 2017 Irrevocable Trust, and the Marisa Shey Gorovitz 2017 Irrevocable Trust. Elizabeth Gorovitz is the wife of Aaron Gorovitz;

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.09 to $1.11. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.09 to $1.20. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.

Donation of 300,000 shares from the Jonathan Javitt Living Trust to the Jonathan Javitt Donor Advised Fund.

Charitable Transfer

Consists of (i) 12,599,997 shares of common stock held by the Jonathan Javitt Living Trust, (ii) 1,422,000 shares of common stock held by The Javitt 2012 Irrevocable Dynasty Trust, (iii) 146,332 shares of common stock held by Jonathan Javitt individually and (iv) 300,000 held by the Jonathan Javitt Donor Advised Fund. Jonathan Javitt is the trustee of the Jonathan Javitt Living Trust, the Grantor of The Javitt 2012 Irrevocable Dynasty Trust and the donor and primary advisor of the Jonathan Javitt Donor Advised Fund.

Private sale pursuant to an option granted by the Reporting Person in 2017 in support of a financing for NeuroRx, Inc. Purchaser has agreed to hold the shares for a period of one year.

Held by the Jonathan Javitt Living Trust. The Reporting Person is a trustee of the Trust.

Sale was pursuant to the terms of a 10b5-1 trading plan established on June 13, 2022.

Held by Glytech LLC of which the Reporting Person is the sole owner.

Sale was pursuant to the terms of a 10b5-1 trading plan established on June 13, 2022.

Held by Glytech LLC of which the Reporting Person is the sole owner.

Held by the Whitney Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee.

Held by the Lindsay Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee.

Held by the Lindsay Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee.

Held by the Whitney Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee.

The form of ownership has been changed from Indirect to Direct. The original Form 4 stated that these shares were purchased though a 401(k) plan. This Form 4/A is being filed to correct this error.

Total number of shares held is reduced by 40 shares to correct an arithmetic error in the original Form 4.

The form of ownership has been changed from Indirect to Direct. The original Form 4 stated that these shares were purchased though a 401(k) plan. This Form 4/A is being filed to correct this error.

The form of ownership has been changed from Indirect to Direct. The original Form 4 stated that these shares were purchased though a 401(k) plan. This Form 4/A is being filed to correct this error.

The original Form 4 disclosed that the price reported in Column 4 is a weighted average price. This Form 4/A is being filed to amend such information. The shares were purchased in a single transaction at $1.10.

Sale was pursuant to the terms of a 10b5-1 trading plan established on June 13, 2022.

Held by Glytech LLC of which the Reporting Person is the sole owner.

The price reported in Column 4 is a weighted average price. The original Form 4 did not disclose the range of prices that the shares were purchased pursuant to this transaction. This Form 4/A is being filed to include such ranges. These shares were purchased in multiple transactions at prices ranging from $1.10 to $1.01. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.

Sale was pursuant to the terms of a 10b5-1 trading plan established on June 13, 2022.

Held by Glytech LLC of which the Reporting Person is the sole owner.

The price reported in Column 4 is a weighted average price. The original Form 4 did not disclose the range of prices that the shares were purchased pursuant to this transaction. This Form 4/A is being filed to include such ranges. These shares were purchased in multiple transactions at prices ranging from $1.00 to $0.93. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.

Sale was pursuant to the terms of a 10b5-1 trading plan established on June 13, 2022.

Held by Glytech LLC of which the Reporting Person is the sole owner.

Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for NRx Pharmaceuticals, Inc.

Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for NRx Pharmaceuticals, Inc.

Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for NRx Pharmaceuticals, Inc.

Held by Glytech LLC of which the Reporting Person is the sole owner.

Shares were gifted to a charitable remainder unitrust.

Held by Glytech LLC of which the Reporting Person is the sole owner.

Held by Glytech LLC of which the Reporting Person is the sole owner.

Held by Glytech LLC of which the Reporting Person is the sole owner.

Held by Glytech LLC of which the Reporting Person is the sole owner.

Options issued under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on March 8, 2023, generally subject to the Reporting Person's continued service for NRX Pharmaceuticals, Inc.

From an option grant dated November 15, 2020; subject to certain conditions, the options will generally vest at a rate of 2066 every month commencing on 11/30/2020 through 10/30/1022 and the final 2,082 shares on 11/30/2022. As of September 1, 2021, 20,666 shares had vested and were available for exercise.

Shares and restricted stock units acquired pursuant to the exercise of 20,666 vested stock options under the Plan. The Reporting person received 13,164 freely tradable shares of Common Stock and 7,502 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022.

Shares and restricted stock units acquired pursuant to the exercise of 20,666 vested stock options under the Plan. The Reporting person received 13,164 freely tradable shares of Common Stock and 7,502 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022.

Shares and restricted stock units acquired pursuant to the exercise of 28,916 vested stock options under the Plan. The Reporting person received 18,420 freely tradable shares of Common Stock and 10,496 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022.

From an option grant dated September 1, 2020; subject to certain conditions, the options will generally vest in 24 equal installments every month commencing on 09/30/2020 and fully vesting on 09/30/2022. As of September 1, 2021, 22,923 options had vested and were available for exercise.

Shares and restricted stock units acquired pursuant to the exercise of 28,916 vested stock options under the Plan. The Reporting person received 18,420 freely tradable shares of Common Stock and 10,496 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022.

The options are fully vested.

Shares and restricted stock units acquired pursuant to the exercise of 28,724 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the "Plan"). The Reporting person received 18,300 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the "Common Stock") and 10,424 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. The restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022.